Intelligent Bio Solutions (NASDAQ:INBS) versus DexCom (NASDAQ:DXCM) Head to Head Analysis

Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) and DexCom (NASDAQ:DXCM – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Risk and Volatility

Intelligent Bio Solutions has a beta of 4.48, indicating that its share price is 348% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.

Insider & Institutional Ownership

33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 2.8% of Intelligent Bio Solutions shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Intelligent Bio Solutions and DexCom”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intelligent Bio Solutions $4.22 million 1.52 -$12.43 million ($6.38) -0.30
DexCom $4.66 billion 6.51 $836.30 million $2.55 31.92

DexCom has higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intelligent Bio Solutions and DexCom’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intelligent Bio Solutions -269.28% -150.00% -83.38%
DexCom 19.42% 37.77% 15.98%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Intelligent Bio Solutions and DexCom, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intelligent Bio Solutions 1 1 0 0 1.50
DexCom 0 2 24 2 3.00

DexCom has a consensus price target of $95.50, suggesting a potential upside of 17.34%. Given DexCom’s stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than Intelligent Bio Solutions.

Summary

DexCom beats Intelligent Bio Solutions on 13 of the 15 factors compared between the two stocks.

About Intelligent Bio Solutions

(Get Free Report)

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a life sciences company focused on developing and commercializing non-invasive diagnostic and screening technologies. Its primary product is the Intelligent Bio Solutions Drug Screening System, a portable platform designed to detect drugs of abuse through sweat collected from a person’s fingerprint. The system uses a disposable drug screening cartridge and a handheld reader to analyze fingerprint sweat and provide results rapidly. The company markets the technology for applications such as workplace testing, law enforcement, rehabilitation programs, and other settings that require convenient, observed drug screening.

About DexCom

(Get Free Report)

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.

Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.